159 related articles for article (PubMed ID: 36947475)
1. Once-Weekly Semaglutide in Adolescents with Obesity.
Malozowski S
N Engl J Med; 2023 Mar; 388(12):1145-1146. PubMed ID: 36947475
[No Abstract] [Full Text] [Related]
2. Once-Weekly Semaglutide in Adolescents with Obesity.
Snaith JR; Greenfield JR
N Engl J Med; 2023 Mar; 388(12):1145. PubMed ID: 36947474
[No Abstract] [Full Text] [Related]
3. Once-Weekly Semaglutide in Adolescents with Obesity. Reply.
Weghuber D; Kelly AS; Arslanian S
N Engl J Med; 2023 Mar; 388(12):1146. PubMed ID: 36947476
[No Abstract] [Full Text] [Related]
4. Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg.
Kyrillos JV; O'Neil PM; Wharton S
Postgrad Med; 2022 Jan; 134(sup1):1-4. PubMed ID: 36691310
[No Abstract] [Full Text] [Related]
5. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
[No Abstract] [Full Text] [Related]
6. Once-Weekly Semaglutide Is an Effective Adjunct for Weight Loss in Adults without Diabetes Who Are Overweight or Obese.
Slawson DC
Am Fam Physician; 2021 Jul; 104(1):96-97. PubMed ID: 34264618
[No Abstract] [Full Text] [Related]
7. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
[TBL] [Abstract][Full Text] [Related]
8. [Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].
Scheen AJ
Rev Med Liege; 2019 Sep; 74(9):488-494. PubMed ID: 31486321
[TBL] [Abstract][Full Text] [Related]
9. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
[TBL] [Abstract][Full Text] [Related]
10. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
Johansen P; Sandberg A; Capehorn M
Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
[TBL] [Abstract][Full Text] [Related]
11. Semaglutide: First Global Approval.
Dhillon S
Drugs; 2018 Feb; 78(2):275-284. PubMed ID: 29363040
[TBL] [Abstract][Full Text] [Related]
12. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B
J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199
[No Abstract] [Full Text] [Related]
13. The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.
Li X; Qie S; Wang X; Zheng Y; Liu Y; Liu G
Endocrine; 2018 Dec; 62(3):535-545. PubMed ID: 30101378
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.
Tan X; Cao X; Zhou M; Zou P; Hu J
Expert Opin Investig Drugs; 2017 Sep; 26(9):1083-1089. PubMed ID: 28741970
[TBL] [Abstract][Full Text] [Related]
15. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.
Hunt B; Malkin SJP; Moes RGJ; Huisman EL; Vandebrouck T; Wolffenbuttel BHR
BMJ Open Diabetes Res Care; 2019; 7(1):e000705. PubMed ID: 31641522
[TBL] [Abstract][Full Text] [Related]
16. Wegovy (semaglutide): a new weight loss drug for chronic weight management.
Singh G; Krauthamer M; Bjalme-Evans M
J Investig Med; 2022 Jan; 70(1):5-13. PubMed ID: 34706925
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
Aroda VR; Ahmann A; Cariou B; Chow F; Davies MJ; Jódar E; Mehta R; Woo V; Lingvay I
Diabetes Metab; 2019 Oct; 45(5):409-418. PubMed ID: 30615985
[TBL] [Abstract][Full Text] [Related]
18. Semaglutide Is a New Once-Daily Oral Medication to Treat Type 2 Diabetes.
Blakely KK; Weaver K
Nurs Womens Health; 2020 Oct; 24(5):370-376. PubMed ID: 32890462
[TBL] [Abstract][Full Text] [Related]
19. [The glucagon-like peptide-1 receptor-agonist semaglutide].
Boje AD; Juhl CR; Torekov SS; Madsbad S
Ugeskr Laeger; 2019 Oct; 181(41):. PubMed ID: 31610830
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
Lingvay I; Catarig AM; Frias JP; Kumar H; Lausvig NL; le Roux CW; Thielke D; Viljoen A; McCrimmon RJ
Lancet Diabetes Endocrinol; 2019 Nov; 7(11):834-844. PubMed ID: 31540867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
